Epigenetic therapy in MDS and acute AML
Decitabine
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
Clinical experience with decitabine in North American patients with myelodysplastic syndrome
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia
Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia
Decitabine activates specific caspases downstream of p73 in myeloid leukemia
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t (8;21) acute myeloid leukemia blasts
Results of a phase 2 study of valproic acid alone or in combination with all- trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia